(RTTNews) - ADC Therapeutics. (ADCT) is scheduled to host a conference call today at 8:00 a.m. EST to provide an update on its LOTIS-7 trial. LOTIS-7 is a Phase 1b open-label clinical trial evaluating ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ...

The MarketWatch News Department was not involved in the creation of this content. ZYNLONTA(R) in combination with glofitamab (COLUMVI(R)) demonstrated an 89.8% ORR and 77.6% CR across the 49 ...

LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that ...

Reporter focusing on environmental policy, public health issues and climate impacts. Brady Dennis is a Pulitzer Prize-winning reporter for The Washington Post, focusing on the environmental and ...

The following slide deck was published by ADC Therapeutics SA in conjunction with this event.

The LOTIS-7 trial is evaluating ZYNLONTA in combination with glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma. This article was generated with the support of ...

LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026 Company to host conference call today at ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.